» Articles » PMID: 15316238

A Cytokine-based Neuroimmunologic Mechanism of Cancer-related Symptoms

Overview
Date 2004 Aug 19
PMID 15316238
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

While many of the multiple symptoms that cancer patients have are due to the disease, it is increasingly recognized that pain, fatigue, sleep disturbance, cognitive dysfunction and affective symptoms are treatment related, and may lead to treatment delays or premature treatment termination. This symptom burden, a subjective counterpart of tumor burden, causes significant distress. Progress in understanding the mechanisms that underlie these symptoms may lead to new therapies for symptom control. Recently, some of these symptoms have been related to the actions of certain cytokines that produce a constellation of symptoms and behavioral signs when given exogenously to both humans and animals. The cytokine-induced sickness behavior that occurs in animals after the administration of infectious or inflammatory agents or certain proinflammatory cytokines has much in common with the symptoms experienced by cancer patients. Accordingly, we propose that cancer-related symptom clusters share common cytokine-based neuroimmunologic mechanisms. In this review, we provide evidence from clinical and animal studies that correlate the altered cytokine profile with cancer-related symptoms. We also propose that the expression of coexisting symptoms is linked to the deregulated activity of nuclear factor-kappa B, the transcription factor responsible for the production of cytokines and mediators of the inflammatory responses due to cancer and/or cancer treatment. These concepts open exciting new avenues for translational research in the pathophysiology and treatment of cancer-related symptoms.

Citing Articles

The Impact of Chemotherapy and Body Mass Index on Cancer-Related Fatigue in Colon Cancer Patients: A PROFILES-Registry Study.

Kastelein A, Mols F, Kervezee L, Chavannes N, Gelderblom H, Neefjes J Cancer Med. 2025; 14(1):e70536.

PMID: 39757797 PMC: 11702450. DOI: 10.1002/cam4.70536.


Paclitaxel triggers molecular and cellular changes in the choroid plexus.

Zamani A, EmamiAref P, Kubickova L, Hasanova K, Sandor O, Dubovy P Front Pain Res (Lausanne). 2024; 5:1488369.

PMID: 39654799 PMC: 11625821. DOI: 10.3389/fpain.2024.1488369.


Qualitative Classification of Late Systemic Symptoms in Head and Neck Cancer Survivors.

Schoenberg P, Wulff-Burchfield E, Schlundt D, Bonnet K, Dietrich M, Murphy B Cancers (Basel). 2024; 16(11).

PMID: 38893225 PMC: 11172150. DOI: 10.3390/cancers16112106.


Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.

Barratt D, Klepstad P, Dale O, Kaasa S, Somogyi A Pharmacogenomics J. 2024; 24(3):18.

PMID: 38824169 PMC: 11144121. DOI: 10.1038/s41397-024-00339-w.


Trajectories of Inflammatory Markers and Post-COVID-19 Cognitive Symptoms: A Secondary Analysis of the CONTAIN COVID-19 Randomized Trial.

Frontera J, Betensky R, Pirofski L, Wisniewski T, Yoon H, Ortigoza M Neurol Neuroimmunol Neuroinflamm. 2024; 11(3):e200227.

PMID: 38626359 PMC: 11087048. DOI: 10.1212/NXI.0000000000200227.